PIK3CA and lymphangioma: Consistent with the clinical data and previous studies on a mouse model of PIK3CA-driven generalized lymphatic anomaly16, we found that Rapamycin inhibited lymphatic vascular growth in the experimental model of PIK3CAH1047R-driven microcystic LM.